Skip to Content

AtheroNova Inc AHROQ

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

AtheroNova Inc is a clinical stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. The company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion-dollar prescription drug market: cardiovascular disease and stroke prevention.

Contact
2301 Dupont Drive, Suite 525
Irvine, CA, 92612
T +1 949 476-1100
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2014
Fiscal Year End Dec 31, 2014
Stock Type Distressed
Employees 3